CompletedPhase 1NCT01850238

Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Axon Neuroscience SE
Principal Investigator
Reinhold Schmidt, Professor
Medizinische Universität Graz
Intervention
AADvac1(biological)
Enrollment
30 enrolled
Eligibility
50-85 years · All sexes
Timeline
2013 – 2015

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01850238 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials